THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY
🇨🇳China
Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma
Recruiting
- Conditions
- Skeletal Muscle RadiodensityScr/CysC RatioMyosteatosisPancreatic Ductal Adenocarcinoma
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 240
- Registration Number
- NCT05584852
- Locations
- 🇨🇳
the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
Phase 4
Not yet recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 60
- Registration Number
- NCT05559268
A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis
Completed
- Conditions
- Portal Vein ThrombosisSystemic Inflammatory Markers
- Interventions
- Diagnostic Test: clinical laboratory tests, and imaging characteristics
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 478
- Registration Number
- NCT05541562
- Locations
- 🇨🇳
the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor
Early Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: HS-IT101
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 8
- Registration Number
- NCT05539768
Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 35
- Registration Number
- NCT05512416
Clinical Trial of Jinzhen Oral Liquid in Treating Children With COVID-19 Infection
Not Applicable
- Conditions
- COVID-19Child, Only
- Interventions
- Drug: Jinzhen oral liquid or Jinhuaqinggan granules
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 240
- Registration Number
- NCT05507489
- Locations
- 🇨🇳
Phase I Clinical Research Center, Qingdao, Shandong, China
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer
Early Phase 1
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Biological: HS-IT101
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 10
- Registration Number
- NCT05505812
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
Phase 1
Not yet recruiting
- Conditions
- DLBCL
- Interventions
- Combination Product: Selinexor combined with Prednisone, Etoposide, and Lenalidomide
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 67
- Registration Number
- NCT05498636
- Locations
- 🇨🇳
the affiliated hospital of Qingdao University, Qingdao, Shandong, China
Moderate Sedation Combined With Acupuncture Anesthesia in Gastroscopy and Colonoscopy on Screening Research
Not Applicable
Completed
- Conditions
- Gastrointestinal Endoscopy
- Interventions
- Procedure: eletroacupuncture(transcutaneous electrical acupuncture point stimulation )Drug: placebo needle
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 108
- Registration Number
- NCT05485064
- Locations
- 🇨🇳
Jixiangyu, Qingdao, Shandong, China
Bioequivalence Study of Ezetimibe Tablets Under Fed Conditions in Healthy Subjects
Phase 1
- Conditions
- PharmacokineticsSafety
- Interventions
- Behavioral: Test Preparation-Reference preparation-Reference preparationBehavioral: Reference preparation-Reference preparation-Test PreparationBehavioral: Reference preparation-Test Preparation-Reference preparation
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 48
- Registration Number
- NCT05481385
- Locations
- 🇨🇳
Phase I clinical research center, Qingdao, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath